- Home
- EONR vs CLRB Comparison
EONR vs CLRB Comparison
Compare EONR & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- CLRB
- Stock Information
- Founded
- EONR 2020
- CLRB 2002
- Country
- EONR United States
- CLRB United States
- Employees
- EONR N/A
- CLRB N/A
- Industry
- EONR
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- EONR
- CLRB Health Care
- Exchange
- EONR NYSE
- CLRB Nasdaq
- Market Cap
- EONR 10.7M
- CLRB 10.7M
- IPO Year
- EONR N/A
- CLRB N/A
- Fundamental
- Price
- EONR $0.53
- CLRB $0.25
- Analyst Decision
- EONR Strong Buy
- CLRB Buy
- Analyst Count
- EONR 1
- CLRB 2
- Target Price
- EONR $4.50
- CLRB $28.00
- AVG Volume (30 Days)
- EONR 128.5K
- CLRB 3.9M
- Earning Date
- EONR 02-15-2025
- CLRB 11-18-2024
- Dividend Yield
- EONR N/A
- CLRB N/A
- EPS Growth
- EONR N/A
- CLRB N/A
- EPS
- EONR N/A
- CLRB N/A
- Revenue
- EONR $21,714,016.00
- CLRB N/A
- Revenue This Year
- EONR N/A
- CLRB N/A
- Revenue Next Year
- EONR N/A
- CLRB N/A
- P/E Ratio
- EONR N/A
- CLRB N/A
- Revenue Growth
- EONR N/A
- CLRB N/A
- 52 Week Low
- EONR $0.51
- CLRB $0.23
- 52 Week High
- EONR $6.00
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- CLRB 5.84
- Support Level
- EONR N/A
- CLRB $0.23
- Resistance Level
- EONR N/A
- CLRB $0.28
- Average True Range (ATR)
- EONR 0.00
- CLRB 0.07
- MACD
- EONR 0.00
- CLRB -0.11
- Stochastic Oscillator
- EONR 0.00
- CLRB 1.41
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.